Literature DB >> 20627348

Comparison of the replication and persistence of simian-human immunodeficiency viruses expressing Vif proteins with mutation of the SLQYLA or HCCH domains in macaques.

Kimberly Schmitt1, M Sarah Hill, Zhenqian Liu, Autumn Ruiz, Nathan Culley, David M Pinson, Edward B Stephens.   

Abstract

The Vif protein of primate lentiviruses interacts with APOBEC3 proteins, which results in shunting of the APOBEC3-Vif complex to the proteosome for degradation. Using the simian-human immunodeficiency virus (SHIV)/macaque model, we compared the replication and pathogenicity of SHIVs that express a Vif protein in which the entire SLQYLA (SHIV(Vif5A)) or HCCH (SHIV(VifHCCH(-))) domains were substituted with alanine residues. Each virus was inoculated into three macaques and various viral and immunological parameters followed for 6 months. All macaques maintained stable circulating CD4+ T cells, developed low viral loads, maintained the engineered mutations, yielded no histological lesions, and developed immunoprecipitating antibodies early post-inoculation. Sequence analysis of nef and vpu from three lymphoid tissues revealed a high percentage of G-to-A-substitutions. Our results show that while the presence of HCCH and SLQYLA domains are critical in vivo, there may exist APOBEC3 negative reservoirs that allow for low levels of viral replication and persistence but not disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20627348      PMCID: PMC2974619          DOI: 10.1016/j.virol.2010.04.017

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  53 in total

1.  Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.

Authors:  Xianghui Yu; Yunkai Yu; Bindong Liu; Kun Luo; Wei Kong; Panyong Mao; Xiao-Fang Yu
Journal:  Science       Date:  2003-10-16       Impact factor: 47.728

2.  Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes.

Authors:  D H Gabuzda; K Lawrence; E Langhoff; E Terwilliger; T Dorfman; W A Haseltine; J Sodroski
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

3.  A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins.

Authors:  Heather L Wiegand; Brian P Doehle; Hal P Bogerd; Bryan R Cullen
Journal:  EMBO J       Date:  2004-05-20       Impact factor: 11.598

4.  Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome.

Authors:  Qin Yu; Renate König; Satish Pillai; Kristopher Chiles; Mary Kearney; Sarah Palmer; Douglas Richman; John M Coffin; Nathaniel R Landau
Journal:  Nat Struct Mol Biol       Date:  2004-04-18       Impact factor: 15.369

5.  Cell-free transmission of Vif mutants of HIV-1.

Authors:  L Fan; K Peden
Journal:  Virology       Date:  1992-09       Impact factor: 3.616

6.  Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication.

Authors:  Yong-Hui Zheng; Dan Irwin; Takeshi Kurosu; Kenzo Tokunaga; Tetsutaro Sata; B Matija Peterlin
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

7.  Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells.

Authors:  U von Schwedler; J Song; C Aiken; D Trono
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

8.  Transcomplementation of VIF- HIV-1 mutants in CEM cells suggests that VIF affects late steps of the viral life cycle.

Authors:  D Blanc; C Patience; T F Schulz; R Weiss; B Spire
Journal:  Virology       Date:  1993-03       Impact factor: 3.616

9.  Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles.

Authors:  H Sakai; R Shibata; J Sakuragi; S Sakuragi; M Kawamura; A Adachi
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

10.  The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.

Authors:  Ann M Sheehy; Nathan C Gaddis; Michael H Malim
Journal:  Nat Med       Date:  2003-10-05       Impact factor: 53.440

View more
  7 in total

1.  Analysis of the N-terminal positively charged residues of the simian immunodeficiency virus Vif reveals a critical amino acid required for the antagonism of rhesus APOBEC3D, G, and H.

Authors:  Kimberly Schmitt; Miki Katuwal; Yaqiong Wang; Cicy Li; Edward B Stephens
Journal:  Virology       Date:  2013-12-05       Impact factor: 3.616

2.  Differential virus restriction patterns of rhesus macaque and human APOBEC3A: implications for lentivirus evolution.

Authors:  Kimberly Schmitt; Kejun Guo; Malinda Algaier; Autumn Ruiz; Fang Cheng; Jianming Qiu; Silke Wissing; Mario L Santiago; Edward B Stephens
Journal:  Virology       Date:  2011-08-25       Impact factor: 3.616

3.  First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G.

Authors:  Ming Li; Shivender M D Shandilya; Michael A Carpenter; Anurag Rathore; William L Brown; Angela L Perkins; Daniel A Harki; Jonathan Solberg; Derek J Hook; Krishan K Pandey; Michael A Parniak; Jeffrey R Johnson; Nevan J Krogan; Mohan Somasundaran; Akbar Ali; Celia A Schiffer; Reuben S Harris
Journal:  ACS Chem Biol       Date:  2012-01-17       Impact factor: 5.100

4.  The Binding Interface between Human APOBEC3F and HIV-1 Vif Elucidated by Genetic and Computational Approaches.

Authors:  Christopher Richards; John S Albin; Özlem Demir; Nadine M Shaban; Elizabeth M Luengas; Allison M Land; Brett D Anderson; John R Holten; John S Anderson; Daniel A Harki; Rommie E Amaro; Reuben S Harris
Journal:  Cell Rep       Date:  2015-11-25       Impact factor: 9.423

5.  Lentivirus restriction by diverse primate APOBEC3A proteins.

Authors:  Kimberly Schmitt; Kejun Guo; Miki Katuwal; Darayu Wilson; Courtney Prochnow; Ronda Bransteitter; Xiaojiang S Chen; Mario L Santiago; Edward B Stephens
Journal:  Virology       Date:  2013-05-04       Impact factor: 3.616

6.  Role of cullin-elonginB-elonginC E3 complex in bovine immunodeficiency virus and maedi-visna virus Vif-mediated degradation of host A3Z2-Z3 proteins.

Authors:  Jingyao Zhang; Jiaxin Wu; Weiran Wang; Hui Wu; Bin Yu; Jiawen Wang; Mingyu Lv; Xiaodan Wang; Haihong Zhang; Wei Kong; Xianghui Yu
Journal:  Retrovirology       Date:  2014-09-12       Impact factor: 4.602

7.  Combined Antiviral Therapy Using Designed Molecular Scaffolds Targeting Two Distinct Viral Functions, HIV-1 Genome Integration and Capsid Assembly.

Authors:  Wannisa Khamaikawin; Somphot Saoin; Sawitree Nangola; Koollawat Chupradit; Supachai Sakkhachornphop; Sudarat Hadpech; Nattawat Onlamoon; Aftab A Ansari; Siddappa N Byrareddy; Pierre Boulanger; Saw-See Hong; Bruce E Torbett; Chatchai Tayapiwatana
Journal:  Mol Ther Nucleic Acids       Date:  2015-08-25       Impact factor: 10.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.